Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older

PQRI Data Collection Sheet						
			/ / □ Male □ Female			
atient's Name Practice Medical Record Nu	mber (MRN)		Birth Date (mm/dd/yyyy) Gender			
Clinical Information Step 1 Is patient eligible for this measure?			Date of Service Billing Information			
				Yes	No	Code Required on Claim Form
Patient is aged 50 years and older on date of encounter.			Verify date of birth on claim form.			
Patient has a line item diagnosis of fracture of the hip, spine or distal radius AND a CPT Code for this visit OR			Refer to coding specifications document for list of applicable codes. Codes determining a patient's			
Patient has a line item diagnosis of fracture of the hip, spine or distal radius or osteoporosis AND there is a CPT Procedure Code.			eligibility must be reported on the same claim as the quality code(s) identified below.			
If No is checked for any of the above, STOP. Do not repo a CPT category II code.	rt					
Step 2 Does patient meet or have an acceptable reason for not meeting the measure?						
Central Dual-Energy X-ray Absorptiometry (DXA) Measurement OR Pharmacologic Therapy'	Yes	No	Code to be Reported on Line 24D of Paper Claim Form, if <i>Yes</i> (or Service Line 24 of Electronic Claim Form)			
DXA ordered			3096F			
DXA performed			3095F			
Pharmacologic therapy prescribed ²			4005F			
Not ordered, performed or prescribed for one of the following reasons:						
 Medical (eg, not indicated, contraindicated, other medical reason) 			3096F-1P OR 3095F-1P OR 4005-1P			
Patient (eg, patient declined, economic, social, religious, other patient reason)			3096F-2P OR 3095F-2P OR 4005F-2P			
 System (eg, resources to perform the services not available, other reason attributable to health care delivery system) 			3096F-3P OR 3095F-3P OR 4005F-3P			
Document reason here and in medical chart.			If No is checked for all of the above, report 3096F–8P OR 3095F–8P OR 4005F–8P (Central DXA measurement was not ordered or performed and a pharmacologic therapy for osteoporosis was not prescribed, reason not otherwise specified.)			

Note: This measure should be reported at one of the following two instances if management following fracture has occurred or is planned within 3 months of fracture.

Prior DXA status or already on pharmacologic therapy pre-fracture meets this measure

¹⁾ During an office visit with ICD-9-CM diagnosis code for fracture of hip, spine or distal radius OR

²⁾ At the time of a procedure to repair a fracture

Osteoporosis

Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older

continued from previous page		

¹Pharmacologic Therapy: U.S. Food and Drug Administration approved pharmacologic options for osteoporosis prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, ibandronate, and risedronate), calcitonin, estrogens (estrogens and/or hormone therapy), parathyroid hormone [PTH (1-34), teriparatide], and selective estrogen receptor modules or SERMs (raloxifene).

²"Prescribed" may include prescription given to the patient for treatment of osteoporosis (as listed above) at one or more encounters during the reorting period, OR documentation that patient is already taking pharmacologic therapy for osteoporosis, as documented in the current medication list.